Shopping Cart 0
Cart Subtotal
AED 0

arGEN-X BV (ARGX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 0

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 0

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 0

Details

arGEN-X BV (arGEN-X) discovers and develops antibody drugs based on its proprietary antibody platforms. Its product pipeline includes ARGX-110, ARGX-111 and ARGX-115 for the treatment of various types of cancers such as T-cell lymphoma, nasopharyngeal cancer, chronic myelogenous leukemia, MET amplified cancer and others. ARGX-113 and ARGX-110 are for the treatment of autoimmune diseases. arGEN-X develops antibodies using its proprietary technology platforms such as NHance, SIMPLE antibody technology and others. The company's products are used for the treatment of cancer and inflammatory and autoimmune diseases. It has operations in the Netherlands and Belgium. arGEN-X is headquartered in Breda, the Netherlands.

arGEN-X BV (ARGX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

arGEN-X BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

arGEN-X BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

arGEN-X BV, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

arGEN-X Raises US$6.7 Million In Extended Series B Financing 12

arGEN-X Secures US$37 Million In Series B Financing Round 13

Partnerships 15

Argenx Enters into Agreement with Broteio Pharma 15

Argen-X to Partner with AbbVie 15

Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 16

arGEN-X Enters into Co-Development Agreement with Leo Pharma 17

ArGEN-X Enters into Agreement with US Based Biotech Company 18

arGEN-X Enters into Agreement with Catholic University of Louvain 19

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 19

Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 20

arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 21

Licensing Agreements 22

Staten Biotech Exercises Option for Licensing Agreement with Argen-X for ARGX-116 22

Shire Extends its Licensing Agreement with ArGEN-X 23

ArGEN-X Enters into Licensing Agreement with University of Bern 24

Lonza Enters into Licensing Agreement with arGEN-X 25

Biowa And Lonza Enter Into Licensing Agreement With arGEN-X For Potelligent CHOK1SV 25

arGEN-X Enters Into Licensing Agreement With de Duve Institute 27

ArGEN-X Enters Into Licensing Agreement For NHance Technology 28

RuiYi Enters Into Licensing Agreement With arGEN-X For ARGX-109 28

arGEN-X Enters Into Licensing Agreement With University of Texas Southwestern Medical Center For NHance Technology 29

arGEN-X Enters Into Licensing Agreement With Biowa 30

arGEN-X Enters Into Licensing Agreement With Eli Lilly 31

Equity Offering 32

Argenx Files Draft Registration Statement for Public Offering of Shares 32

Argenx Raises USD33.4 Million in Private Placement of Shares 33

arGEN-X Raises USD17.4 Million in Private Placement of Shares 34

arGEN-X Completes Exercise of Underwriter's Over Allotment Option for IPO for USD56.8 Million 35

arGEN-X BV-Key Competitors 38

Key Employees 39

Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Financial Announcements 41

Mar 10, 2016: argenx reports fourth quarter business update and full year 2015 financial results 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

arGEN-X BV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

arGEN-X BV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9


List Of Table

List of Tables

arGEN-X BV, Pharmaceuticals & Healthcare, Key Facts, 2015 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

arGEN-X BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

arGEN-X BV, Deals By Therapy Area, 2011 to YTD 2017 9

arGEN-X BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

arGEN-X Raises US$6.7 Million In Extended Series B Financing 12

arGEN-X Secures US$37 Million In Series B Financing Round 13

Argenx Enters into Agreement with Broteio Pharma 15

Argen-X to Partner with AbbVie 15

Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 16

arGEN-X Enters into Co-Development Agreement with Leo Pharma 17

ArGEN-X Enters into Agreement with US Based Biotech Company 18

arGEN-X Enters into Agreement with Catholic University of Louvain 19

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 19

Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 20

arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 21

Staten Biotech Exercises Option for Licensing Agreement with Argen-X for ARGX-116 22

Shire Extends its Licensing Agreement with ArGEN-X 23

ArGEN-X Enters into Licensing Agreement with University of Bern 24

Lonza Enters into Licensing Agreement with arGEN-X 25

Biowa And Lonza Enter Into Licensing Agreement With arGEN-X For Potelligent CHOK1SV 25

arGEN-X Enters Into Licensing Agreement With de Duve Institute 27

ArGEN-X Enters Into Licensing Agreement For NHance Technology 28

RuiYi Enters Into Licensing Agreement With arGEN-X For ARGX-109 28

arGEN-X Enters Into Licensing Agreement With University of Texas Southwestern Medical Center For NHance Technology 29

arGEN-X Enters Into Licensing Agreement With Biowa 30

arGEN-X Enters Into Licensing Agreement With Eli Lilly 31

Argenx Files Draft Registration Statement for Public Offering of Shares 32

Argenx Raises USD33.4 Million in Private Placement of Shares 33

arGEN-X Raises USD17.4 Million in Private Placement of Shares 34

arGEN-X Completes Exercise of Underwriter's Over Allotment Option for IPO for USD56.8 Million 35

arGEN-X BV, Key Competitors 38

arGEN-X BV, Key Employees 39

arGEN-X BV, Subsidiaries 40

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

arGEN-X BV (arGEN-X) discovers and develops antibody drugs based on its proprietary antibody platforms. Its product pipeline includes ARGX-110, ARGX-111 and ARGX-115 for the treatment of various types of cancers such as T-cell lymphoma, nasopharyngeal cancer, chronic myelogenous leukemia, MET amplified cancer and others. ARGX-113 and ARGX-110 are for the treatment of autoimmune diseases. arGEN-X develops antibodies using its proprietary technology platforms such as NHance, SIMPLE antibody technology and others. The company's products are used for the treatment of cancer and inflammatory and autoimmune diseases. It has operations in the Netherlands and Belgium. arGEN-X is headquartered in Breda, the Netherlands.

arGEN-X BV (ARGX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

arGEN-X BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

arGEN-X BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

arGEN-X BV, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

arGEN-X Raises US$6.7 Million In Extended Series B Financing 12

arGEN-X Secures US$37 Million In Series B Financing Round 13

Partnerships 15

Argenx Enters into Agreement with Broteio Pharma 15

Argen-X to Partner with AbbVie 15

Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 16

arGEN-X Enters into Co-Development Agreement with Leo Pharma 17

ArGEN-X Enters into Agreement with US Based Biotech Company 18

arGEN-X Enters into Agreement with Catholic University of Louvain 19

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 19

Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 20

arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 21

Licensing Agreements 22

Staten Biotech Exercises Option for Licensing Agreement with Argen-X for ARGX-116 22

Shire Extends its Licensing Agreement with ArGEN-X 23

ArGEN-X Enters into Licensing Agreement with University of Bern 24

Lonza Enters into Licensing Agreement with arGEN-X 25

Biowa And Lonza Enter Into Licensing Agreement With arGEN-X For Potelligent CHOK1SV 25

arGEN-X Enters Into Licensing Agreement With de Duve Institute 27

ArGEN-X Enters Into Licensing Agreement For NHance Technology 28

RuiYi Enters Into Licensing Agreement With arGEN-X For ARGX-109 28

arGEN-X Enters Into Licensing Agreement With University of Texas Southwestern Medical Center For NHance Technology 29

arGEN-X Enters Into Licensing Agreement With Biowa 30

arGEN-X Enters Into Licensing Agreement With Eli Lilly 31

Equity Offering 32

Argenx Files Draft Registration Statement for Public Offering of Shares 32

Argenx Raises USD33.4 Million in Private Placement of Shares 33

arGEN-X Raises USD17.4 Million in Private Placement of Shares 34

arGEN-X Completes Exercise of Underwriter's Over Allotment Option for IPO for USD56.8 Million 35

arGEN-X BV-Key Competitors 38

Key Employees 39

Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Financial Announcements 41

Mar 10, 2016: argenx reports fourth quarter business update and full year 2015 financial results 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

arGEN-X BV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

arGEN-X BV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9


List Of Table

List of Tables

arGEN-X BV, Pharmaceuticals & Healthcare, Key Facts, 2015 1

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

arGEN-X BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

arGEN-X BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

arGEN-X BV, Deals By Therapy Area, 2011 to YTD 2017 9

arGEN-X BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

arGEN-X Raises US$6.7 Million In Extended Series B Financing 12

arGEN-X Secures US$37 Million In Series B Financing Round 13

Argenx Enters into Agreement with Broteio Pharma 15

Argen-X to Partner with AbbVie 15

Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 16

arGEN-X Enters into Co-Development Agreement with Leo Pharma 17

ArGEN-X Enters into Agreement with US Based Biotech Company 18

arGEN-X Enters into Agreement with Catholic University of Louvain 19

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 19

Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 20

arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 21

Staten Biotech Exercises Option for Licensing Agreement with Argen-X for ARGX-116 22

Shire Extends its Licensing Agreement with ArGEN-X 23

ArGEN-X Enters into Licensing Agreement with University of Bern 24

Lonza Enters into Licensing Agreement with arGEN-X 25

Biowa And Lonza Enter Into Licensing Agreement With arGEN-X For Potelligent CHOK1SV 25

arGEN-X Enters Into Licensing Agreement With de Duve Institute 27

ArGEN-X Enters Into Licensing Agreement For NHance Technology 28

RuiYi Enters Into Licensing Agreement With arGEN-X For ARGX-109 28

arGEN-X Enters Into Licensing Agreement With University of Texas Southwestern Medical Center For NHance Technology 29

arGEN-X Enters Into Licensing Agreement With Biowa 30

arGEN-X Enters Into Licensing Agreement With Eli Lilly 31

Argenx Files Draft Registration Statement for Public Offering of Shares 32

Argenx Raises USD33.4 Million in Private Placement of Shares 33

arGEN-X Raises USD17.4 Million in Private Placement of Shares 34

arGEN-X Completes Exercise of Underwriter's Over Allotment Option for IPO for USD56.8 Million 35

arGEN-X BV, Key Competitors 38

arGEN-X BV, Key Employees 39

arGEN-X BV, Subsidiaries 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS